Natco Pharma Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "NATCO receives approval from Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India".
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma has received approval from India's Central Drugs Standard Control Organisation (CDSCO) to launch Semaglutide in the Indian market. Semaglutide is a GLP-1 receptor agonist widely used for treating type 2 diabetes and has gained strong demand globally for weight management as well. This positions Natco to compete in a high-growth therapeutic segment currently dominated by innovator brands like Novo Nordisk's Ozempic and Wegovy. The approval gives Natco a pathway to commercial launch and potentially capture market share in India.
Positive for shareholders — regulatory clearance for a high-demand drug opens a new, sizeable revenue stream. Stock could see positive momentum on news of pricing and launch timelines, though actual financial impact depends on how quickly commercial sales ramp up.